中国药科大学为教育部直属、国家“211工程”和“985工程优势学科创新平台”建设高校，是一所以药学为特色的多科性、研究型大学。其中药学、中药学学科为龙头的药学学科群建设始终保持国内领先水平。2017年，成为国家“双一流”建设高校。学校建有“多靶标天然药物”全国重点实验室和省部级重点实验室、工程技术中心以及创新平台，实现了化学药、中药、生物药三大领域科研平台的全覆盖，为各类新药的研发提供全方位服务。
无锡高新区是全市生物医药产业的最前沿和主阵地，全区拥有各类生物医药企业700多家，形成了“创新药物及制剂、创新药物研发何生产服务、医疗器械及诊断试剂、智慧医疗及健康服务、特殊食品”五大领域、“I·Campus（无锡国际生命科学创新园）、无锡新加坡生命科学创新园、无锡特殊食品产业园”三大品牌园区、“阿斯利康、药明、济民可信、纽迪希亚”等X家龙头企业生态圈为支撑的“5+3+X”生命科学产业集聚发展新格局。
中国药科大学无锡创新研究院是由中国药科大学和无锡高新区管委会共同创办的事业单位，现有科研场地3万平方米。作为校地协同创新标杆项目，该研究院的建立既是贯彻国家“十四五”生物经济发展规划、落实创新驱动发展战略的关键实践，也是深化校市战略合作、构筑"政产学研用"一体化生态的里程碑成果。研究院锚定全球生物医药前沿领域，构建"8+N"创新矩阵：以创新药物研发为龙头，同步建设皮肤健康研究中心、药物递释技术研究中心、泛核酸创新药物研究中心、高端医疗器械研究中心、特定人群健康产品研究中心、合成生物学研究中心、特色中药复方制剂及天然产物研究中心等八大支柱板块，配套搭建公共仪器技术服务平台、药学动物实验中心平台等公共服务平台，形成覆盖"基础研究-中试放大-产业转化"的全链条创新体系。通过实施"核心技术攻关、知识产权运营、创新生态培育"三维驱动战略，着力破解行业"卡脖子"技术瓶颈。
China Pharmaceutical University (CPU) I is one of the state “211 Project” and “985 Project Innovation Platform key universities affiliated to the Ministry of Education. CPU is a multi-disciplinary and research-oriented university with pharmacy as its characteristics. The construction of pharmaceutical discipline groups with pharmacy and traditional Chinese pharmacy as its leading disciplines has always maintained the leading role in China. In 2017, it became a member of the“Double First-class”construction universities.It has established the national key labs of Multi-target Natural Medicine, key labs at provincial or ministerial levels, engineering technical centers, and innovative platforms, realizing the full coverage of the scientific research platforms in the fields of chemical medicine, traditional Chinese pharmacy and biological medicine, and providing all-round services for the research and development of various new drugs.
Wuxi National Hi-Tech District stands at the forefront and main battlefield of the city's biomedical industry. The zone boasts over 700 various biomedical enterprises, forming a new pattern of "5+3+X" life science industry agglomeration development, supported by five major fields: "innovative drugs and preparations, innovative drug research and development and production services, medical devices and diagnostic reagents, smart healthcare and health services, and special foods", three brand parks: "I·Campus, Wuxi Singapore Life Science Innovation Park, and Wuxi Special Food Industrial Park", and X leading enterprise ecosystems such as "AstraZeneca, WuXi AppTec, Jimin Trust, and Nutricia".
Wuxi Innovation Research Institute of China Pharmaceutical University is a public institution jointly founded by China Pharmaceutical University and the Management Committee of Wuxi high tech Zone, with an existing scientific research site of 30000 square meters. As a benchmark project of University local collaborative innovation, the establishment of the Institute is not only the key practice of implementing the national "14th five year" bioeconomy development plan and implementing the innovation driven development strategy, but also a milestone achievement of deepening the strategic cooperation between the University and the city and building an ecological integration of "government, industry, University, research and application". The Institute has anchored in the Global Frontier of biomedicine and built an "8+n" innovation matrix: led by the research and development of innovative drugs, it has simultaneously built eight pillar sectors, including the skin health research center, the drug delivery technology research center, the pan nucleic acid innovative drug research center, the high-end medical device Research Center, the health product research center for specific populations, the synthetic biology research center, and the Research Center for characteristic traditional Chinese medicine compound preparations and natural products. It has also built public service platforms such as the public instrument technology service platform and the pharmaceutical animal experiment center platform, forming a full chain innovation system covering "basic research pilot scale-up industrial transformation". Through the implementation of the three-dimensional driving strategy of "tackling key problems in core technology, operating intellectual property rights, and cultivating innovation ecology", efforts have been made to break the "neck" technology bottleneck in the industry.
